Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

NCT00651508 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: KOS-1584

Sponsor

Bristol-Myers Squibb